GITAM University Professor Creates Revolutionary Multi-Cancer Diagnostic Platform
In a significant breakthrough for oncology diagnostics, Dr. Shanti Latha Pandrangi, an associate professor at GITAM Deemed to be University in Visakhapatnam, has successfully developed a prototype miniaturized diagnostic platform capable of detecting multiple cancer types. This innovative project, supported by the Department of Science and Technology's NIDHI scheme, represents a major step toward making comprehensive cancer screening more accessible and affordable across India and potentially worldwide.
CanDect Dx: A Portable Serum-Based Diagnostic System
The diagnostic platform, named CanDect Dx, functions as a portable, serum-based system designed to revolutionize how cancer is detected in clinical settings. Unlike traditional diagnostic methods that often require expensive imaging or invasive procedures, this device analyzes peripheral blood serum using a sophisticated multiplex screening approach. The core innovation lies in its utilization of six patented protein biomarkers that Dr. Pandrangi identified through extensive translational research conducted at GITAM University.
These biomarkers enable the device to screen for nine different cancer types: breast, ovarian, cervical, uterine, prostate, liver, lung, oral, and brain cancers. This comprehensive coverage addresses a critical gap in conventional diagnostics, which typically rely on single-analyte markers that can only detect one specific cancer type at a time.
Advanced Validation and Standardization Process
The prototype has already undergone rigorous standardization using 350 patient samples, establishing a solid foundation for its diagnostic capabilities. Currently, validation is actively underway on an additional 2,000 to 3,000 samples to further refine diagnostic thresholds and enhance both sensitivity and specificity. This extensive validation process ensures the device meets stringent clinical standards before potential deployment in healthcare settings.
"Early detection is especially critical for internal malignancies, which often present with nonspecific symptoms and are frequently diagnosed at advanced stages," explained Dr. Shanti Latha Pandrangi. "Widespread screening using such technologies could shift cancer management toward earlier intervention, improving prognosis and potentially transforming cancer into a more manageable and treatable condition."
Affordable Alternative to Conventional Diagnostic Methods
Designed as a cost-effective alternative to expensive diagnostic procedures like CT scans, PET scans, and immunohistochemistry (IHC), the CanDect Dx platform could significantly reduce diagnostic costs while enabling earlier cancer detection. This affordability factor is particularly important in resource-limited settings where access to advanced medical imaging remains challenging.
Dr. Pandrangi envisions integrating this diagnostic platform into routine annual health screenings as a preventive diagnostic tool, potentially transforming how healthcare systems approach cancer surveillance. The device's portability further enhances its utility in remote or underserved areas where traditional diagnostic infrastructure may be limited.
Commercialization Through Biotechnology Startup
The project is being advanced through ImmuCelTek Private Limited, Dr. Pandrangi's biotechnology startup, which is actively seeking funding for large-scale validation and regulatory readiness. This commercial pathway demonstrates the practical application potential of academic research in addressing real-world healthcare challenges.
Dr. Shanti Latha Pandrangi's contributions to cancer research have earned her numerous accolades, including GITAM's Best Researcher Award for 2025, the prestigious EMBO fellowship, and the Global Health Award from Hong Kong University. Her international collaborations as a member of both the European and American Associations for Cancer Research further underscore the global significance of her work in advancing oncology diagnostics.
